Puretech Health Plc (PRTC) has released an update.
PureTech Health Plc has launched Seaport Therapeutics with a $100 million oversubscribed Series A financing round and announced significant management transitions, including the appointment of Bharatt Chowrira as CEO of PureTech and the promotion of Eric Elenko to President. Founding CEO Daphne Zohar will now lead Seaport as CEO, aiming to advance neuropsychiatric programs with the backing of leading biotech investors. The company’s strategic initiatives and hub-and-spoke R&D model underscore its commitment to developing innovative medicines, maintaining financial independence, and delivering shareholder value without public market fundraising for over six years.
For further insights into PRTC stock, check out TipRanks’ Stock Analysis page.
